Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirus–Positive Oropharyngeal Carcinoma

Stefano Cavalieri, MD1; Mara S. Serafini, MSc2; Andrea Carenzo, MSc2; Silvana Canevari, PhD2; Ruud H. Brakenhoff, PhD4; C. René Leemans, MD4; Irene H. Nauta, MD4; Frank Hoebers, MD, PhD5; Mari F. C. M. van den Hout, MD, PhD5; Kathrin Schechenbach, MD7; Thomas K. Hoffmann, MD8; Laura Ardighieri, MD9; Tito Poli, MD10; Pasquale Quattrone, MD11; Laura D. Locati, MD, PhD1; Lisa Licitra, MD, PhD1,12; and Loris De Cecco, PhD2

PURPOSE Under common therapeutic regimens, the prognosis of human papillomavirus (HPV)–positive squamous oropharyngeal carcinomas (OPCs) is more favorable than HPV-negative OPCs. However, the prognosis of some tumors is dismal, and validated prognostic factors are missing in clinical practice. The present work aimed to validate the prognostic significance of our published three-cluster model and to compare its prognostic value with those of the 8th edition of the tumor-node-metastasis staging system (TNM8) and published signatures and clustering models.

METHODS Patients with HPV DNA-positive OPCs with locoregionally advanced nonmetastatic disease treated with curative intent (BD2Decide observational study, NCT02832102) were considered as validation cohort. Patients were treated in seven European centers, with expertise in the multidisciplinary management of patients with head and neck cancer. The median follow-up was 46.2 months (95% CI, 41.2 to 50), and data collection was concluded in September 2019. The primary end point of this study was overall survival (OS). Three-clustering models and seven prognostic signatures were compared with our three-cluster model.

RESULTS The study population consisted of 235 patients. The three-cluster model confirmed its prognostic value. Two-year OS in each cluster was 100% in the low-risk cluster, 96.6% in the intermediate-risk cluster, and 86.3% in the high-risk cluster ($P = .00074$). For the high-risk cluster, we observed an area under the curve = 0.832 for 2-year OS, significantly outperforming TNM 8th edition (area under the curve = 0.596), and functional and biological differences were identified for each cluster.

CONCLUSION The rigorous clinical selection of the cases included in this study confirmed the robustness of our three-cluster model in HPV-positive OPCs. The prognostic value was found to be independent and superior compared with TNM8. The next step includes the translation of the three-cluster model in clinical practice. This could open the way to future exploration of already available therapies in HPV-positive OPCs tailoring de-escalation or intensification according to the three-cluster model.

JCO Precis Oncol 5:1666-1676. © 2021 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License

INTRODUCTION Among head and neck squamous cell carcinomas (HNSCCs), the incidence of oropharyngeal cancer (OPC) has been increasing in the past few decades. This is mainly due to the increasing number of human papillomavirus (HPV)–related OPCs.1 The first findings of HPV infection in HNSCC have been reported by European research groups in the 1980s,2 followed by a first causal association by expression analysis and a link to the OPC in the 1990s.3 The association between HPV-positive OPC and the positive prognostic impact has been described approximately 10 years later.4 The favorable prognosis of patients with HPV-positive OPC led to explore treatment de-escalation in recent clinical trials. However, expectations were in contrast with the results because this approach was associated with poorer outcomes. Thus, standard of care has not been changed.5,6 Therefore, there is still a strong need for trustworthy prognostic factors.7,8 Different preclinical and clinical studies have been performed leading to the identification of several genomic, epigenomic, transcriptomic, and proteomic characteristics of HPV-positive OPCs.9-14 At present, the most relevant clinical prognostic factors are stage, extranodal extension (ENE), and smoking exposure.15 ENE is currently part of the AJCC and UICC staging system for HPV-negative HNSCCs, but not for HPV-positive ones. In particular, in p16-negative OPC and non-OPC HNSCCs, clinical or radiologic ENE is considered for cN staging, and histopathologic ENE for pN one. Nonetheless, its negative prognostic impact was found in HPV-positive OPC as well, so some authors suggested its
implementation in refining the cN of the 8th edition of the tumor-node-metastasis staging system (TNM8).16 In the field of gene expression (GE) profiling, the pioneering studies of Slebos9 and Pyeon17 (referred to the initial characterization of potential biomarkers able to differentiate HPV-positive from HPV-negative HNSCC) and numerous omics characteristics of HPV-positive OPCs were identified in preclinical and clinical studies.9-14 Additionally, the analysis of HNSCC transcriptomic data highlighted the existence of HPV-positive distinctive prognostic clusters. In particular, we published a meta-analysis of publicly available transcriptomic data sets of HPV-positive HNSCC, in which three different clusters were characterized. Our three-cluster model was commented and compared with previous HPV-positive HNSCC subtypes in a recent comprehensive review.18 Moreover, Dhawan19 performed a meta-analysis of OPC data sets with available survival data to determine whether currently available GE signatures could prognosticate outcome more accurately than established clinicopathologic predictors.

Exploiting a well-characterized homogenous HPV-positive OPC cohort with locoregionally advanced disease treated with curative intent,20 the present study aims to validate the prognostic significance of our previously identified three-cluster model and to compare its prognostic value with those of TNM8 and the most relevant already published signatures and clustering models.

METHODS

Patient Selection

Patients with HNSCC with locoregionally advanced disease (stages III and IV according to TNM 7th edition21) and treated with curative intent had been included in the project Big Data and Models for Personalized Head and Neck Cancer Decision Support (BD2Decide).20 The study was approved by institutional review boards and ethical committee in March 2016, and patients consented to enrollment. The study population included 1,537 patients diagnosed and treated between 2008 and 2017, and the follow-up closed in September 2019. In this work, data and analyses are focused on patients with HPV-positive OPC. To reduce confounding variables affecting oncologic outcome and consequentially prognostic accuracy of the proposed model, we excluded (1) patients with p16-positive but HPV DNA-negative OPC22 and (2) patients receiving unimodal treatment (surgery without postoperative radiation or exclusive radiotherapy without concomitant systemic treatments) for clinical stage T1N1, T2N1, and T3-T4 any N disease.

HPV Status and Transcriptomic Experiments

Standard HPV testing was performed on OPC samples by p16 immunohistochemistry, followed by, in case of p16-positive immunostaining, a HPV DNA test.20 In case of polymerase chain reaction (PCR), p16-positive cases were tested using the GP5+/6+ DNA PCR assay, aimed at detecting 14 high-risk HPV types (ie, HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). If DNA PCR was negative, HPV16 E7 primers were used to exclude L1 integrations.

In case of in situ hybridization, p16-positive OPC specimens were tested using the INFORM HPV III Family 16 Probe, able to identify 10 high-risk HPV types (ie, HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66). If DNA PCR was negative, HPV16 E7 primers were used to exclude L1 integrations.

In case of in situ hybridization, p16-positive OPC specimens were tested using the INFORM HPV III Family 16 Probe, able to identify 10 high-risk HPV genotypes (ie, HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66). When the DNA was not evaluable through in situ hybridization, the E6/E7 mRNA of high-risk HPV was assessed through the RNA scope Probe HPV HR18, identifying HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82. Positive results in both p16 immunohistochemistry and HPV DNA testing were considered evidence of a transcriptionally active HPV infection.23 GE data sets had been
generated using Affymetrix human Clariom D microarrays (Affymetrix, Santa Clara, CA). MIAME-compliant data are deposited in the GEO repository (GSE163173).

Bioinformatics Analysis

After microarray data normalization, the HPV-positive OPC selected cohort was classified according to the three-cluster model. Tumor microenvironment, the immune and stroma scores, and other cell components were inferred by xCell. Pairwise gene set enrichment analysis (GSEA) comparisons were performed to discern which Hallmark gene sets were differentially enriched. In the final data set, we assessed the overall survival (OS) prognostic discrimination ability of our three-cluster model by area under the curve (AUC) at 2 years, and its performance was challenged against TNM and publicly available prognostic models and signatures:

(A) HPV-positive OPC signatures: (A1) Gleber-Netto and (A2) Chen;
(B) HNSCC signatures: (B1) De Cecco 172 genes and (B2) De Cecco Hypoxia signature able to identify aggressive tumors; and
(C) multiple cancers signatures: (C1) Torres-Roca RSI directly proportional to radioresistance and (C2) Buffa Hypoxia. Moreover, three already described signatures (Slebos-up, Pyeon-up, and Zhang), clustering HPV-positive OPC, were applied to our final data set and compared with our three-cluster model. Three signatures (radiosensitivity index [RSI], De Cecco Hypoxia, and De Cecco 172 genes) were applied following the linear model provided in the original studies. Regarding the other models, a metagene approach was applied: A score was computed in our data set by ssGSEA using the GSVA R package providing an unsupervised method for estimating variation of gene set enrichment through the samples. AUC at 2 years was assessed through timeROC R package.

To enable a better understanding of strengths and limits of the available signatures, studies and their characteristics are summarized in the Data Supplement.

Statistical Analysis

Differences between the survival curves of the three clusters were assessed using the log-rank test and R package survival. Primary end point was OS, and secondary end point was disease-free survival (DFS). For survival analyses, we set 2 years of observation. Further details are provided in the Data Supplement.

RESULTS

Definition of the Final Data Set

In the BD2Decide project, 624 patients with stage III-IV (TNM 7th edition) OPC were included, and 377 patients were p16-positive. For validation analysis, we analyzed the cohort composed of 286 p16-positive cases with informative transcriptomics. Among them, 235 p16-positive and HPV-positive cases (14 excluded because of HPV DNA-negative and 37 excluded because of single-modality treatments) were suitable as a final data set for clinical correlations (Fig 1). No significant differences were recorded between the cohorts (Data Supplement). In the final data set, the median follow-up was 46.2 months (95% CI, 41.2 to 50), 79% of patients were men (185), and the median age was 60 years (Table 1). Of the 225 cases with regional lymph node involvement, 18% had a radiologic and/or clinical ENE, defined as the radiologic and/or clinical evidence of cancer invasion through nodal capsule or beyond. Two thirds of patients were current or previous smokers at diagnosis, and 71% of them had a tobacco exposure of > 10 pack-years. According to the prognostic stratification of 36 from the work of Ang et al, 68% of patients with HPV-positive OPCs had a low-risk disease and the remaining 32% of cases were at intermediate risk (74 patients; unknown in one case). According to the current TNM staging system (TNM8), disease stage was I in 48% of cases (112 patients), II in 27% (64 patients), and III in 25% (59 patients). By applying the three-cluster model to the 235 data set, the following distribution was observed: low risk or Cl1, 108 (46%) cases; high risk or Cl2, 30 (13%)
| Clinical Variable | Total (235) | Low Risk or Cl1 (108 [46]) | High Risk or Cl2 (30 [13]) | Intermediate Risk or Cl3 (97 [41]) | P* |
|-------------------|-------------|-----------------------------|----------------------------|----------------------------------|----|
| Sex, No. (%)      |             |                             |                            |                                  | .982 |
| Men               | 185 (79)    | 85 (80)                     | 76 (78)                    | 76 (78)                          |    |
| Women             | 50 (21)     | 23 (20)                     | 21 (22)                    | 21 (22)                          |    |
| Median age at diagnosis, years, range | 60 (40-84) | 60 (40-76) | 60.5 (42-84) | 59 (45-77) | .459 |
| Stage (TNM 7th edition), No. (%) |             |                             |                            |                                  | .325 |
| III               | 44 (19)     | 26 (24)                     | 6 (20)                     | 12 (13)                          |    |
| IVa               | 166 (70.5)  | 71 (66)                     | 21 (70)                    | 74 (76)                          |    |
| IVb               | 25 (10.5)   | 11 (10)                     | 3 (10)                     | 11 (11)                          |    |
| Stage (TNM 8th edition), No. (%) |             |                             |                            |                                  | .902 |
| I                 | 112 (48)    | 54 (50)                     | 13 (43)                    | 45 (46)                          |    |
| II                | 64 (27)     | 30 (28)                     | 8 (27)                     | 26 (27)                          |    |
| III               | 59 (25)     | 24 (22)                     | 9 (30)                     | 26 (27)                          |    |
| T1-3 N3           | 4           | 3                           | 0                          | 1                                |    |
| T4 N0-2           | 51          | 20                          | 9                          | 22                               |    |
| T4 N3             | 4           | 1                           | 0                          | 3                                |    |
| Clinical N stage, No. (%) |             |                             |                            |                                  | .243 |
| cN0               | 10 (4)      | 4 (4)                       | 3 (10)                     | 3 (3)                            |    |
| cN1-3             | 225 (96)    | 104 (96)                    | 27 (90)                    | 94 (97)                          |    |
| ENE-positive      | 40 (18)     | 13 (12.5)                   | 10 (37)                    | 17 (18)                          | .012 |
| ENE-negative      | 185 (82)    | 91 (87.5)                   | 17 (63)                    | 77 (82)                          |    |
| Smoking, No. (%)  |             |                             |                            |                                  | .505 |
| Current or former | 156 (66)    | 76 (70)                     | 19 (64)                    | 61 (63)                          |    |
| Never             | 74 (32)     | 30 (28)                     | 10 (33)                    | 34 (35)                          |    |
| Unknown           | 5 (2)       | 2 (2)                       | 1 (3)                      | 2 (2)                            |    |
| Risk according to Ang KK 2010, No. (%) |             |                             |                            |                                  | .464 |
| Low               | 160 (68)    | 77 (71)                     | 21 (70)                    | 62 (64)                          |    |
| Intermediate      | 74 (31)     | 31 (29)                     | 8 (27)                     | 35 (36)                          |    |
| Unknown (pack-years NR) | 1 (1)       | —                           | 1 (3)                      | —                                |    |
| Alcohol, No. (%)  |             |                             |                            |                                  | .995 |
| Current or former | 116 (49)    | 54 (50)                     | 15 (50)                    | 47 (48)                          |    |
| Never             | 113 (48)    | 52 (48)                     | 15 (50)                    | 46 (48)                          |    |
| Unknown           | 6 (3)       | 2 (2)                       | —                         | 4 (4)                            |    |
| ECOG PS, No. (%)  |             |                             |                            |                                  | .01 (ECOG 0 v 1-2) |
| 0                 | 162         | 86                          | 16                         | 60                               |    |
| 1                 | 35          | 10                          | 6                          | 19                               |    |
| 2                 | 3           | 0                           | 1                          | 2                                |    |
| Unknown           | 35          | 12                          | 7                          | 16                               |    |
| ACE27, No. (%)    |             |                             |                            |                                  | .521 (0 v 1-3) |
| 0                 | 101 (43)    | 48 (44)                     | 10 (33)                    | 43 (44)                          |    |
| 1                 | 95 (40)     | 43 (40)                     | 12 (40)                    | 40 (41)                          |    |
| 2                 | 34 (15)     | 15 (14)                     | 6 (20)                     | 13 (14)                          |    |
| 3                 | 5 (2)       | 2 (2)                       | 2 (7)                      | 1 (1)                            |    |

(Continued on following page)
TABLE 1. Clinical Characteristics and Treatment Modalities of the Patients With Oropharyngeal Cancer Considered for the Final Data Set and Their Clusterization According to the Three-Cluster Prognostic Model (Continued)

| Clinical Variable | Total (235) | Low Risk or Cl1 (108 [46]) | High Risk or Cl2 (30 [13]) | Intermediate Risk or Cl3 (97 [41]) | P* |
|-------------------|-------------|-----------------------------|----------------------------|-----------------------------------|----|
| Treatment modalities, No. (%) | .354        |                             |                            |                                   |    |
| 3                 | 29 (12)     | 14 (12)                     | 5 (17)                     | 10 (10)                           |    |
| 2                 | 186 (79)    | 81 (75)                     | 23 (77)                    | 82 (85)                           |    |
| Radiotherapy plus chemotherapy | 172         | 74                          | 19                         | 79                                |    |
| Surgery plus radiotherapy | 14          | 7                           | 4                          | 3                                 | .354|
| 1                 | 20 (9)      | 13 (13)                     | 2 (6)                      | 5 (5)                             |    |
| Radiotherapy      | 19          | 13                          | 2                          | 5                                 |    |
| Surgery           | 1           | 1                           | —                          | —                                 | —   |

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; ENE, extranodal extension; NR, not reported; TNM, tumor-node-metastasis.

*P values were obtained by Wilcoxon (age) and Chi-squared (other clinical characteristics) tests. The significance level was set to .05 (bold entries).

Prognostic Analysis

The prognostic stratification according to the three-cluster model was tested in both the validation (Data Supplement) and final data sets (Fig 2A) and confirmed the rank order of the three-cluster model obtained in the original meta-analysis (Data Supplement).24 The 2-year OS differed among the three clusters (low risk 100%, high risk 86.3%, and intermediate risk 96.9%; P = .00074). Considering low risk as a reference group, hazard ratio for death was 9.15 (95% CI, 2.42 to 34.5; P = .001) for high versus low risk and 5.67 (95% CI, 1.64 to 19.6; P = .006) for intermediate versus low risk. AUC for 2-year OS was 0.832 (Data Supplement). Considering 2-year OS, AUC was 0.754 for TNM8 versus 0.596 for TNM7 (Data Supplement).

Survival and recurrence probability were predicted with statistical significance by TNM8 (Fig 2B), not by TNM7 (Data Supplement). Through an alluvial plot, the distribution of patients according to the TNM7 and TNM8 classification and the three clusters was explored (Fig 2C; Data Supplement). Table 2 reports the OS prognostic power at 2 years for TNM8 (AUC 0.754) and seven publicly available prognostic signatures. Besides the three-cluster model, three signatures (two hypoxia signatures32 and RS31) outperformed TNM8 and were able to significantly separate high-risk versus low-risk HPV-positive OPC cases. Box plot distribution (Data Supplement), according to the scores of the seven selected prognostic signatures in each of the three clusters, confirmed that the high risk exhibited significantly the highest RSI and hypoxia expression. The clustering was not influenced by TNM staging also at multivariate analysis (OS: three-cluster model P = .0056 v TNM8 P = .073; DFS: three-cluster model P = .0008 v TNM8 P = .031), and the combination of three-cluster model and TNM8 provided AUC = 0.842 for OS and AUC = 0.809 for DFS (Data Supplement) at 2 years. At bivariate analysis, the three clusters maintained their prognostic power (OS P = .009, DFS P = .001) independently of ENE status (Fig 2D and Data Supplement). Two-year DFS was 99.1% in low risk, 76.2% in high risk, and 91.8% in intermediate risk (P = .0002). Using low risk as reference, hazard ratio for disease recurrence was 6.1 (95% CI, 2.37 to 15.76; P = .0002) for high versus low risk and 3.67 (95% CI, 1.57 to 8.59; P = .0027) for intermediate versus low risk. AUC for 2-year DFS was 0.777 (Data Supplement). The highest AUCs were observed for the three-cluster model. AUC classification was prognostic for DFS (P = .039), not for OS (P = .069; Data Supplement).

Tumor Biological Landscape

Three signatures reported molecular patterns associated with HPV status9,17,37 these signatures and their performance in stratifying HPV tumors were investigated and compared with our three-cluster model (Fig 3). The stratification ability of pioneering signatures9,17 was not confirmed because of the limited sample size (Fig 3A and Fig 3B). On the other hand, a significant difference was observed with Zhang clustering (Fig 3C), and the distribution in the three clusters confirmed the similarity, as already highlighted in the review by Qin et al.18 The samples of the final data set, subdivided according to the three-cluster model, were analyzed for difference in cell composition by xCell bioinformatics tool (Data Supplement), essentially confirming the results obtained in the original study.25 The highest level of immune score was recorded in low risk (P = 2.8 × 10−6; Fig 4A). When the immune populations were explored in detail, we observed a significant enrichment of total or memory CD4 T cells, effector memory CD8 T cells, and B cells in low risk, followed by
intermediate risk and high risk (Data Supplement). The highest level of stroma score was reached in high risk ($P = .00018$, Fig 4B); the detailed analysis of the microenvironment revealed an abundance in fibroblasts, keratinocytes, and endothelial cells in high risk, while epithelial cells characterized both high and intermediate risks (Data Supplement). To gain a deeper insight into the biological and functional differences among the three clusters, analysis of the 50 hallmark gene sets in GSEA was performed in the final data set (Fig 4C). According to GSEA, high risk exhibited a strong enrichment of 26 of 50 hallmark gene sets versus low and intermediate risk (Data Supplement), and 18 gene sets were in common. In particular, we observed enrichment: in high versus low risk, in epithelial mesenchymal transition (development), glycolysis (metabolism), UV response (DNA damage), NOTCH signaling, TGF beta signaling, hypoxia (pathway), mitotic spindle, p53 pathway, and MYC target V1 (proliferation); in intermediate versus low risk in metabolic activation; and in common in high and intermediate versus low risk, in MTORC1 (signaling), reactive oxygen species (pathway), cholesterol homeostasis, and xenobiotic metabolism (metabolism). Sixteen GSEA pathways are characterized by immune-exhausted HNSCCs. Among them, 38 pathways were overexpressed in high risk, 15 in intermediate risk, and 10 in low risk (Data Supplement).

**DISCUSSION**

This is an independent validation of a three-cluster model, previously developed through meta-analysis of publicly available data sets. The main difference between the original and present data sets relies on the current study...
cohort. Our original meta-analysis had a limitation since the cases were HNSCC HPV-positive, but 32% of them were non-OPC. The present analysis considered only HPV-positive locoregionally advanced OPC patients treated with curative intent. All the HPV-positive not OPCs together with HPV DNA-negative or suboptimally treated patients were excluded from the final data set. This homogeneous patient series and the availability of controlled clinical and pathologic data led to the refinement of the three-cluster model on the largest data set of OPC presently available. Unsupervised clustering analysis is a popular approach to discover novel biological-oriented disease subtypes. This approach has deeply been applied in breast cancer starting from the early 2000s; the signature was refined and its last version, PAM50, added prognostic value to the traditional pathologic, histologic, and biological parameters. Clustering models of HNSCC associated with HPV have been already developed essentially defining two clusters associated with HPV-positive tumors. However, these studies contained non-OPC HPV-positive HNSCCs and HPV-negative OPCs. In the original meta-analysis, we observed that most of the HPV-positive non-OPC cases belonged to the high-risk cluster. It is noteworthy that the majority of patients (47%, 24 of 51) excluded from the validation set, because of HPV DNA-negative or suboptimally treated, were part of the high-risk cluster. Thus, the results obtained on OPC final data set indicated that, after removal of potential confounding factors, high risk maintained the worst prognosis. The present work definitely confirmed the prognostic value of the three-cluster model in HPV-positive OPCs. The prognostic accuracy of the three-cluster model (AUC = 0.832 for 2-year OS) outperformed the TNM8, the current gold standard for prognostic stratification in oncology, and at bivariate

TABLE 2. Comparison of OS Prognostic Power at 2 Years in Univariate Analysis: Three-Cluster Model Versus TNM8 and Other Available Prognostic Signatures. Ranking on the Basis of AUC Value

| Ranking | Signature                  | AUC for 2-Year OS (95% CI) | P     | Characteristics                          | Notes                                      | Reference                  |
|---------|----------------------------|-----------------------------|-------|------------------------------------------|--------------------------------------------|----------------------------|
| 1       | Three-cluster model        | 0.832 (0.73 to 0.932)       | 1.48e-10 | Prognostic in HPV plus OPC                | Low v intermediate v high risk             | Locati et al             |
| 2       | Hypoxia                    | 0.80 (0.659 to 0.942)       | 3.02e-05 | Prognostic in HNSCC                      | Continuous variable                        | De Cecco et al          |
| 3       | Hypoxia                    | 0.796 (0.619 to 0.974)      | .00108 | Prognostic in multiple cancers            | Continuous variable                        | Buffa et al             |
| 4       | RSI                        | 0.762 (0.632 to 0.892)      | 7.77e-05 | Prognostic in multiple cancers            | Continuous variable                        | Torres-Roca et al       |
| 5       | TNM8                       | 0.754 (0.584 to 0.925)      | .00346 | Prognostic in HPV plus OPC                | Stage I v II v III                         | AJCC and UICC 8th edition |
| 6       | Gleber-Netto               | 0.626 (0.433 to 0.812)      | .201   | Prognostic in HPV plus OPC                | Continuous variable                        | Gleber-Netto et al      |
| 7       | Chen Immune-Related        | 0.612 (0.431 to 0.794)      | .225   | Prognostic in HPV plus OPC                | Continuous variable                        | Chen et al              |
| 8       | 172-gene                   | 0.597 (0.41 to 0.783)       | .31    | Prognostic in HNSCC                      | Continuous variable                        | De Cecco et al          |

Abbreviations: AUC, area under the curve; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; OPC, oropharyngeal carcinoma; OS, overall survival; RSI, radiosensitivity index; TNM8, 8th edition of tumor-node-metastasis staging system.

FIG 3. HPV-clustering models applied to the final data set subdivided in the three-cluster model: (A) box plot of Slebos-UP score, (B) box plot of Pyeon-UP score, and (C) box plot of Zhang score. HPV, human papillomavirus.
analysis, its prognostic role was independent. In addition to the three-cluster model, three prognostic signatures, even if developed in all sites HNSCC or multiple cancers or OPC HPV-negative cases, were also able to outperform TNM8. They significantly separate the OPC HPV-positive cases with an AUC > 0.76. Interestingly, these signatures were obtained by meta-analysis of more than 1,000 samples and/or were validated in different published studies. On the contrary, the other three signatures and models, built on smaller or heterogeneous HNSCC cohorts, did not show a prognostic role, suggesting the importance of larger or homogeneous study design in the context of the omics studies. The prognostic performance of the three-cluster model was not influenced by underlying clinical factors. The only difference in terms of clinical characteristics among the three clusters was ENE prevalence. Indeed, high-risk patients had a higher frequency of ENE plus disease, reflecting a more aggressive disease. This consistent association corroborates the robust independent prognostic ability of the proposed three-cluster model. Low risk was characterized by the best prognosis and included 46% of patients. These tumors expressed a high immune score and significant enrichment of immune active cells (total or memory CD4 T cells, effector memory CD8 T cells, and B cells). They were characterized by a low RSI score and the lowest hypoxia scores. Our low-risk cluster is probably similar to the HPV-IMU identified by Zhang et al, also confirmed by the experimental comparison of Qin et al. The worst prognosis was observed in high-risk patients (13% of the study cohort). This group,
characterized by the highest keratinocytic differentiation status, is similar to the HPV-KRT cluster of Zhang et al and was confirmed in the comparison of Qin et al. Moreover, the high-risk cluster was characterized by the lowest immune score and an enrichment in GSEA pathways associated with the immune-exhausted HNSCC tumors, which is also defined as cold immune. The enrichment in hypoxia hallmark, consistent with the immune suppression and radioresistance (high RSI), was confirmed by the highest expression of hypoxia signatures.

The novelty introduced by our work was the identification of the intermediate-risk cluster (41% of the study cohort), never characterized before by other clustering models. Despite our efforts, this was the less biologically and functionally characterized cluster. Nevertheless, biologically we were able to separate this group from the patients with good (low risk) or poor (high risk) prognosis. In detail, it expressed an intermediate immune score not associated with exhausted immune cells, a marginal radioresistance and low expression of De Cecco hypoxia signature. Notably, we observed an evident enrichment in metabolic pathways in both high and intermediate risks. Further investigation and deeper comments about possible treatments applicable to patients with HPV-positive OPC are reported in the review of Qin et al. On the basis of the experimental comparison of the three-cluster model data with the other published HPV-positive two-cluster models, in addition, we observed that in our study population, the majority of current or previous smokers had a relevant tobacco exposure (> 10 pack-years in 71% of cases). Nevertheless, the frequency of current or previous smokers in our study population (66%) was lower than the one reported in previously published studies (82% in the RTOG0129 trial). This is consistent with the observed smoking reduction in Western countries, where cigarette smoking rates have been reducing in the past 50 years. Moreover, future projections are forecasting a further reduction in smoking prevalence. These epidemiologic variations imply that the observations found in our study population might need further updates in the next decades, to study whether behavioral changes will be reflected by different biological alterations, with possible clinical impact. Potential limitations of the three-cluster model are the observed dropout rate (25%) in our GE case material compared with the original clinical set and the lack of specification of the viral genotype for each case. The first limitation could be due to the fact that for most OPC cases, where chemoradiation is usually preferred over surgery, the analyzed specimen was an initial small biopsy. However, independent studies show that an increase in sample size, corresponding to our dropout rate, had limited effect on the clustering performance. The second drawback could be attributed to the HPV DNA tests used. However, this limitation is mitigated by the fact that the vast majority of HPV-positive OPCs are known to be related to the HPV16 genotype. Indeed, we do not anticipate major negative impacts of the cited drawbacks on our analysis.

In conclusion, in patients with HPV-positive OPC with locoregionally advanced disease treated with curative intent, there is still a strong need for defining trustable prognostic factors, and our results seem to fulfill this necessity. The rigorous clinical selection of the cases included in the BD2Decide study corroborates the robustness of the proposed three-cluster model, which resulted in an independent and superior prognostic factor compared with TNM8, the current gold standard for prognostic forecasting in clinical practice. The next step includes the required translation of this GE clustering in clinical practice, following a framework applied in other tumors. This could open the way to future exploration of already available therapies in HPV-positive OPCs tailoring de-escalation or intensification according to the three-cluster model.

**AFFILIATIONS**

1 Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
2 Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
3 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
4 Amsterdam UMC, Vrije Universiteit Amsterdam, Otolaryngology/Head and Neck Surgery, Cancer Center Amsterdam, the Netherlands
5 Department of Radiation Oncology (MAASTRO), Research Institute GROW, Maastricht University, Maastricht, the Netherlands
6 Department of Pathology, Research Institute GROW, Maastricht University Medical Center, Maastricht, the Netherlands
7 Department of Otolaryngology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
8 Department of Otolaryngology/Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany
9 Department of Pathology, ASST Spedali Civili of Brescia, Brescia, Italy
10 Unit of Maxillofacial Surgery, Department of Medicine and Surgery, University of Parma—University Hospital of Parma, Parma, Italy
11 Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

**CORRESPONDING AUTHOR**

Loris De Cecco, PhD, Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy; e-mail: loris.dececco@istitutotumori.mi.it.

**EQUAL CONTRIBUTION**

S.C. and M.S.S. are co-first authors.

**SUPPORT**

Supported by European Union Horizon 2020 Framework Programme, Grant or Award Number: 689715. AIRC (ID 23573 project—P.I. Loris De Cecco).

**AUTHOR CONTRIBUTIONS**

Conception and design: Silvana Canevari, Ruud H. Brakenhoff, Lisa Licitra, Loris De Cecco
Molecular Subtyping in HPV-Positive Oropharyngeal Carcinoma

Financial support: Loris De Cecco

Provision of study materials or patients: Stefano Cavaliere, Ruud H. Brakenhoff, C. René Leemans, Irene H. Nauta, Frank Hoebers, Mari F. C. M. van den Hout; Kathrin Scheckenbach, Laura Ardighieri, TitO Poli, Lisa Licitra

Collection and assembly of data: Stefano Cavaliere, Silvana Canevari, Ruud H. Brakenhoff, Irene H. Nauta, Frank Hoebers, Mari F. C. M. van den Hout, Kathrin Scheckenbach, Thomas K. Hoffmann, Tito Poli, Pasquale Quattroline, Laura D. Locati, Lisa Licitra, Loris De Cecco

Data analysis and interpretation: Stefano Cavaliere, Mara S. Serafini, Andrea Carenzo, Silvana Canevari, Ruud H. Brakenhoff, C. René Leemans, Frank Hoebers, Laura Ardighieri, Pasquale Quattroline, Laura D. Locati, Lisa Licitra, Loris De Cecco

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rcv or ascopubs.org/po/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

REFERENCES

1. Licitra L, Zigon G, Gatta G, et al: Human papillomavirus in HNSCC: A European epidemiologic perspective. Hematol Oncol Clin North Am 22:1143-1153, vii-viii, 2008
2. Syrjanen K, Syrjanen S, Pyrhönen S: Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas. ORL J Otorhinolaryngol Relat Spec 44:323-334, 1982
3. Snijders PJF, Cromme FV, van den Brule AJ, et al: Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer 51:845-850, 1992
4. Gillison ML: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720, 2000
5. Mehanna H, Robinson M, Hartley A, et al: Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALATE HPV): An open-label randomised controlled phase 3 trial. Lancet 393:51-60, 2019
6. Zsolt L, Trotti AM, Harris J, et al: Radiotherapy plus cetuximab or cisplatin in human papillomavirus-negative oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. Lancet 393:40-50, 2019
7. Chundury A, Kim S: Radiation dose de-escalation in HPV-positive oropharynx cancer: When will it Be an acceptable standard of care? J Clin Oncol 39:947-949, 2021
8. Orlando E, Licitra L: The day after De-ESCALATE and RTOG 1016 trials results. Futur Oncol 15:2069-2072, 2019
9. Slebos RJ, Yi Y, Ely K, et al: Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 12:701-709, 2006
10. De Cecco L, Nicolau M, Giannoccaro M, et al: Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene expression data. Oncotarget 6:9627-9642, 2015
11. Greaney-Davies FST, Risk JM, Robinson M, et al: Essential characterisation of human papillomavirus positive head and neck cancer cell lines. Oral Oncol 103:104613, 2020
12. Prusinkiewicz MA, Gameiro SF, Ghasemi F, et al: Survival-associated metabolic genes in human papillomavirus-positive head and neck cancers. Cancers (Basel) 12:253, 2020
13. Seiwert TY, Zuo Z, Keck MK, et al: Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 21:632-641, 2015
14. Lawrence MS, Sougnez C, Lichtenstein L, et al: Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576-582, 2015
15. O’Sullivan B, Huang SH, Siu LL, et al: Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 31:543-550, 2013
16. Amin MB, Greene FL, Edge SB, et al: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93-99, 2017
17. Pyeon D, Newton MA, Lambert PF, et al: Fundamental differences in cell cycle deregulation in human papillomavirus-positive and -negative head/neck and cervical cancers. Cancer Res 67:4605-4619, 2007
18. Qin T, Li S, Henry LE, et al: Molecular tumor subtypes of HPV-positive head and neck cancers: Biological characteristics and implications for clinical outcomes. Cancers (Basel) 13:2721, 2021
19. Dhawan A, Scott J, Sundaresan P, et al: Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Sci Rep 10:10226, 2020
20. Cavaliere S, De Cecco L, Brakenhoff RH, et al: Development of a multomics database for personalized prognostic forecasting in head and neck cancer. The Big Data to Decide EU Project. Head Neck 43:601-612, 2021 Feb

Frank Hoebers

Consulting or Advisory Role: Bristol Myers Squibb

Thomas K. Hoffmann

Consulting or Advisory Role: Bristol Myers Squibb/Medarex, Merck Serono

Laura D. Locati

Honoraria: McCann Health, Biogen, Bristol Myers Squibb Foundation, Elsai, Lilly, Ipsen, MSD, Merck Serono

Research Funding: Elsai

Travel, Accommodations, Expenses: Elsai, BMS, Merck Serono, MSD

Lisa Licitra

Consulting or Advisory Role: Elsai, Boehringer Ingelheim, AstraZeneca, SOBI, Novartis, Bayer, MSD, Merck Serono, Roche, Bristol Myers Squibb, Incyte, Doxapharma, GlaxoSmithKline, Nanobiotix, Debiopharm Group, Amgen, Ipsen

Research Funding: AstraZeneca, Novartis, Roche, MSD, Elsai, Merck Serono, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Exelixis, IRX Therapeutics, Medpace, Pfizer, Debiopharm Group, Roche

Travel, Accommodations, Expenses: Merck Serono, Bristol Myers Squibb, MSD, Elsai, AstraZeneca

Loris De Cecco

Research Funding: Bristol Myers Squibb Foundation

No other potential conflicts of interest were reported.
21. Edge SB, Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471-1474, 2010
22. Nauta IH, Rietbergen MM, van Bokhoven AAJD, et al: Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing. Ann Oncol 29:1273-1279, 2018
23. Ndiaye C, Mena M, Alenery L, et al: HPV DNA, E6/7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. Lancet Oncol 15:1319-1331, 2014
24. Locati LD, Serafini MS, Ianni MF, et al: Mining of self-organizing map gene-expression portraits reveals prognostic stratification of HPV-positive head and neck squamous cell carcinoma. Cancers (Basel) 11:1057, 2019
25. Aran D, Hu Z, Butte AJ: xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18:220, 2017
26. Subramanian A, Tamayo P, Mootha VK, et al: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15560, 2005
27. Liberzon A, Birger C, Thorvaldsdottir H, et al: The molecular signatures database hallmark gene set collection. Cell Syst. 1:417-425, 2015
28. Gleber-Netto FO, Rao X, Guo T, et al: Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 4:e124762, 2019
29. Chen Y, Nie J, Li X, et al: Identification of immune-related prognostic biomarkers associated with HPV-positive head and neck squamous cell carcinoma. J Immunol Res 2021:6661625, 2021
30. De Cecco L, Bossi P, Locati L, et al: Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. Ann Oncol 25:1628-1635, 2014
31. Torres-Roca JF, Eschrich S, Zhao H, et al: Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 65:7169-7176, 2005
32. Buffa FM, Harris AL, West CM, et al: Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102:428-435, 2010
33. Huang SH, O’Sullivan B, Su J, et al: Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal cancer and its potential role in refining TNM-8 cN-classification. Radiother Oncol 144:13-22, 2020
34. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
35. Zhang Y, Koneva LA, Virani S, et al: Subtypes of HPV-positive head and neck cancers are associated with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway signatures. J Immunol Res 2019:4682713, 2019
36. Aran D, Hu Z, Butte AJ: xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18:220, 2017
37. WHO/Europe | European Tobacco Use: Trends Report 2019. https://www.euro.who.int/en/health-topics/disease-prevention/tobacco/publications/2019/european-tobacco-use-trends-report-2019-2019
38. Taberna M, Mena M, Pavón MA, et al: Human papillomavirus-related oropharyngeal cancer. Ann Oncol 28:2386-2398, 2017

1676 © 2021 by American Society of Clinical Oncology